Conference Videos
Tumor Immunotherapy Symposium: A Clinical Perspective | November 18, 2016
The Tumor Immunotherapy Symposium: A Clinical Perspective was a key educational event organized by the Tumor Immunotherapy Program (TIP) at the Princess Margaret Cancer Centre. For our inaugural Symposium, our objective was to provide a clinical and translational perspective on tumor immunotherapy by highlighting the current and upcoming clinical trials being conducted in this field in Toronto as well as exciting emerging therapies worldwide. Participants learned the current status of clinical trials involving immune checkpoint inhibitors, adoptive cell therapy and oncolytic viruses as well as case-based discussion on the assessment and management of immune related adverse events.
This one-day symposium was held at the MaRS Discovery District in downtown Toronto on November 18, 2016.
Introduction and KEYNOTE: Harnessing the Immune System to Treat Cancer
Dr. Mario Sznol, MD, Yale Cancer Center
Immune Checkpoint Inhibitors and Co-Stimulatory Molecules: Targeting Beyond PD- 1/PD-L1
Dr. Philippe Bedard, MD, Princess Margaret Cancer Centre
Update on Princess Margaret Investigator-Initiated Trials: INSPIRE and METADUR
Dr. Anna Spreafico, MD, Princess Margaret Cancer Centre
Predictive Biomarker Evaluations and Immunophenotyping in Tumor Immunotherapy
Dr. Derek Clouthier, PhD, Princess Margaret Cancer Centre
Panel Discussion #1
Dr. Lillian Siu, Dr. Mario Sznol, Dr. Philippe Bedard, Dr. Anna Spreafico & Dr. Derek Clouthier
Adoptive Cell Therapy
Dr. Marcus Butler, MD, Princess Margaret Cancer Centre
Engineering T Cells in Cancer Therapy: CAR-T, TCR-T and Others
Dr. Naoto Hirano, MD, PhD, Princess Margaret Cancer Centre
T Cell Engager Antibodies - with focus on Hematological Malignancies
Dr. John Kuruvilla, MD, Princess Margaret Cancer Centre
Oncolytic viruses
Dr. Guy Ungerechts, MD, PhD, The Ottawa Hospital Cancer Centre
Panel Dicussion #2
Dr. Marcus Butler, Dr. Naoto Hirano, Dr. John Kuruvilla and Dr. Guy Ungerechts
The Status of PD-L1 Testing and What is Next?
Dr. Ming Tsao, MD, Princess Margaret Cancer Centre